+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide

Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide

European Journal of Nuclear Medicine and Molecular Imaging 39(12): 1868-1875

The biokinetics and dosimetry of (111)In-DOTA-NOC-ATE (NOCATE), a high-affinity ligand of SSTR-2 and SSTR-5, and (111)In-DTPA-octreotide (Octreoscan™, OCTREO) were compared in the same patients. Seventeen patients (10 men, 7 women; mean age 60 years), referred for an OCTREO scan for imaging of a neuroendocrine tumour (15), thymoma (1) or medullary thyroid carcinoma (1), agreed to undergo a second study with NOCATE. Whole-body anterior-posterior scans were recorded 0.5 (100 % reference scan), 4, 24 and 48 h (17 patients) and 120 h (5 patients) after injection. In 16 patients the OCTREO scan (178 ± 15 MBq) was performed 16 ± 5 days before the NOCATE scan (108 ± 14 MBq) with identical timing; 1 patient had the NOCATE scan before the OCTREO scan. Blood samples were obtained from 14 patients 5 min to 48 h after injection. Activities expressed as percent of the initial (reference) activity in the whole body, lung, kidney, liver, spleen and blood were fitted to biexponential or single exponential functions. Dosimetry was performed using OLINDA/EXM. Initial whole-body, lung and kidney activities were similar, but retention of NOCATE was higher than that of OCTREO. Liver and spleen uptakes of NOCATE were higher from the start (p < 0.001) and remained so over time. Whole-body activity showed similar α and β half-lives, but the β fraction of NOCATE was double that of OCTREO. Blood T (1/2)β for NOCATE was longer (19 vs. 6 h). As a result, the effective dose of NOCATE (105 μSv/MBq) exceeded that of OCTREO (52 μSv/MBq), and the latter result was similar to the ICRP 106 value of 54 μSv/MBq. Differential activity measurement in blood cells and plasma showed an average of <5 % of NOCATE and OCTREO attached to globular blood components. NOCATE showed a slower clearance from normal tissues and its effective dose was roughly double that of OCTREO.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 036562865

Download citation: RISBibTeXText

PMID: 22940856

DOI: 10.1007/s00259-012-2210-0

Related references

Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 33(5): 532-540, 2006

Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. Journal of Nuclear Medicine 40(5): 762-767, 1999

Bone marrow dose results in peptide receptor radionuclide therapy with 90Y-DOTA-Tyr3-Octreotide, 111In-DTPA-Octreotide and 177Lu-DOTA-Octreotate Importance of dosimetry model. Journal of Nuclear Medicine 43(5 Suppl.): 90P, 2002

Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results. Melanoma Research 15(6): 523-529, 2005

Somatostatin receptor scintigraphy with 111In-DOTA-Lanreotide and 111In-DOTA-Tyr3-Octreotide in patients with melanoma stage IV In vitro and in vivo results. Journal of Investigative Dermatology 123(2), 2004

Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging 32(10): 1144-1151, 2005

111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study. European Journal of Nuclear Medicine and Molecular Imaging 30(8): 1087-1095, 2003

Imaging of human tumors via 111In DTPA-adenosylcobalamin, 111In DTPA-octreotide, 67Ga and 201Tl. Journal of Nuclear Medicine 43(5 Suppl.): 270P, 2002

111In-DTPA-Tyr3-octreotate Comparison with 111In-DTPA-octreotide in patients. Journal of Nuclear Medicine 41(5 Suppl ): 31P, 2000

Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?. Journal of Nuclear Medicine 46(9): 1561-1569, 2005

Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats. European Journal of Drug Metabolism and Pharmacokinetics 27(1): 37-43, 2002

A case of metastatic gastrinomas in the liver visualized by 111In-DTPA-D-Phe-octreotide (111In-pentetreotide). Kaku Igaku. Japanese Journal of Nuclear Medicine 33(5): 545-549, 1996

Biokinetics of 111In-DTPA-D-Phe1-octreotide in nude mice transplanted with a human carcinoid tumor. Nuclear Medicine & Biology 28(1): 67-73, 2001

A comparison of biodistribution between 111In-DTPA octreotide and 111In-DOTATOC in rats bearing pancreatic tumors. Journal of Veterinary Medical Science 68(4): 367-371, 2006